이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

NewGLAB PharmaLTD 관리

관리 기준 확인 0/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Yoon-Hwa Ko

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	no data
CEO 소유권	n/a
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	데이터 없음

최근 관리 업데이트

업데이트 없음

Recent updates

The NewGLABLTD (KOSDAQ:214870) Share Price Has Gained 274%, So Why Not Pay It Some Attention?

Dec 22

CEO

Yoon-Hwa Ko (55 yo)

no data

테뉴어

Yoon-Hwa Ko serves as the Co-Chief Executive Officer of NewGLAB Pharma CO.,LTD (formerly known as NewGLAB CO.,LTD) (formerly known as HDPRO Co., Ltd.)

NewGLAB PharmaLTD 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

Recent updates

NewGLAB Pharma CO.,LTD announced that it has received KRW 6.835 billion in funding from Namhwa Corporation, SLP Co. Ltd. and other investors

NewGLAB Pharma CO.,LTD announced that it expects to receive KRW 6.835 billion in funding from Namhwa Corporation, SLP Co. Ltd. and other investors

Full year 2022 earnings released: ₩2,201 loss per share (vs ₩1,662 loss in FY 2021)

Now 25% undervalued

NewGLAB Pharma CO.,LTD announced that it has received KRW 25 billion in funding from DB Financial Investment Co.,Ltd., Investment Arm

NewGLAB CO.,LTD announced that it has received KRW 9.23 billion in funding

Full year 2020 earnings released: ₩834 loss per share (vs ₩190 loss in FY 2019)

NewGLAB CO.,LTD announced that it expects to receive KRW 9.23 billion in funding

New 90-day low: ₩10,900

New 90-day low: ₩11,850

The NewGLABLTD (KOSDAQ:214870) Share Price Has Gained 274%, So Why Not Pay It Some Attention?

New 90-day low: ₩12,750

NewGLAB CO.,LTD announced that it expects to receive KRW 35 billion in funding from DB Financial Investment Co.,Ltd., Investment Arm

New 90-day high - ₩15,900

CEO

테뉴어